Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
europe
6
×
europe blog main
6
×
life sciences
national blog main
clinical trials
innovation
brexit
drugs
europe top stories
falsified medicines
labeling
mhra
regulations
uk
eli lilly
fda
national
national top stories
abbvie
alkermes
allergan
arvelle
bms
boehringer ingelheim
boston blog main
boston top stories
bristol-myers squibb
buprenorphine
cariprazine
empagliflozin
european investment fund
felipe jain
financing
funding
gho
healthcare
indiana blog main
indiana top stories
jess fiedorowicz
What
brexit
charting
choppy
course
dynamic
end
medicines
period
plans
post
regulation
regulatory
reveals
transition
uk
drug
fda
alkermes
amsterdam
antipsychotic
approval
benefits
bid
board
boehringer
bristol
caveats
commonly
designed
diabetes
effect
eli
european
expand
fallen
favor
firm
focused
fund
gain
Language
unset
Current search:
europe
×
biotech
×
" europe blog main "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
With Bristol and Otsuka on Board, LSP Raises $620M EU Life Sciences Fund
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System